What happened with RMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ResMed helps people with obstructive sleep apnea keep their airways open during sleep. Its systems deliver pressurized air through a mask, a treatment called continuous positive airway pressure, or CPAP. Devices are its largest revenue source; masks, diagnostic products and accessories supply much of the rest. AirView lets clinicians monitor patients remotely and change device settings, while myAir helps patients use their treatment.
In the Americas, home medical equipment providers typically buy ResMed products, fit them for patients referred by physicians or sleep clinics, and bill insurers or government health programs. Elsewhere, ResMed also sells through distributors and hospitals, and directly to patients in some countries. Sales depend on clinical referrals and adequate insurance coverage and reimbursement. U.S. clearance permits the company to market a device only for the uses in its cleared labeling; clearance does not guarantee insurance coverage.
A smaller business sells Brightree, MatrixCare and MEDIFOX DAN software to home-care and residential-care providers. These customers pay for tools that manage business operations and care, including billing, patient records and staff scheduling. Software revenue depends substantially on customers renewing, upgrading and expanding their agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ResMed’s results depend chiefly on demand for positive-airway-pressure devices and masks; Philips Respironics and Fisher & Paykel, absent from this list, are closer product competitors than most alternatives shown here.
Inspire Medical Systems competes with continued use of ResMed’s mask-based CPAP treatment by selling hospitals and surgery centers an implant that stimulates a nerve to keep the airway open. Watch uptake among U.S. patients whose PAP treatment has failed or who cannot tolerate it—the group eligible for Inspire there.
Eli Lilly’s Zepbound may reduce demand for ResMed’s air-pressure treatment by reducing sleep-apnea severity in adults with obesity and moderate-to-severe obstructive sleep apnea. For ResMed, watch whether patients maintain substantial weight loss, which ResMed says could eventually lessen disease severity.
Apnimed could offer an oral alternative to ResMed’s air-pressure devices if its sleep-apnea drug Oxnimbi is approved and commercialized; it is not yet a marketed product or a source of product sales. The FDA’s February 28, 2027 review target date is the concrete milestone to watch.
Nyxoah offers an alternative to ResMed’s air-pressure devices through Genio, an implanted system that stimulates the nerve controlling tongue movement to keep the airway open. Its Genio sales in the U.S. and Europe are a concrete measure of uptake of this alternative for moderate-to-severe obstructive sleep apnea.
Novo Nordisk’s obesity medicines could change demand for ResMed’s air-pressure treatment by reducing obesity-related sleep-apnea severity, without necessarily removing the need for treatment. Watch sustained weight loss and the sleep apnea that remains afterward, rather than assuming medicine sales replace device demand.
Vivos Therapeutics offers oral appliances as alternatives to ResMed’s air-pressure treatment, while its sleep-practice services overlap with ResMed’s diagnostic business. Watch both appliance sales and the fees Vivos earns for managing diagnostic and consulting services at sleep practices: the overlap extends beyond treatment devices.
ResMed Inc. earningsThis company
ResMed’s report will show whether sales of its sleep and breathing devices and masks can keep growing without cost pressure eroding margins.
Read device revenue and masks-and-other revenue alongside gross margin. If both revenue lines grow while gross margin holds or rises, demand is expanding without ResMed losing ground on the cost of making and delivering its products. Slower device growth or a falling margin would point to weaker demand for the core equipment or costs squeezing profit. Together, these figures show whether ResMed’s growth is supported by both sales and product economics.
Eli Lilly & Co. earningsLLY
Eli Lilly’s report will show whether Zepbound demand is expanding, which could change the future pool of patients using ResMed’s air-pressure treatment.
Look for changes in Lilly’s reported Zepbound sales or demand. Stronger demand means more people may be reached by the weight-loss medicine, widening the potential channel through which weight loss could affect sleep-apnea severity; weaker demand offers less evidence that this channel is expanding. Drug sales do not show whether patients maintain weight loss, whether their sleep apnea improves, or whether they stop using ResMed devices, so the conclusion is about the potential reach of the effect, not realized device losses.
Inspire Medical Systems, Inc. earningsINSP
Inspire Medical Systems’ report will show whether its nerve-stimulation implant is gaining use among U.S. patients who cannot use PAP, an alternative path to treatment for some patients ResMed serves.
Look for growth in Inspire Medical Systems’ sales or procedure volumes, keeping the focus on U.S. patients whose PAP treatment has failed or cannot be tolerated. Faster growth would show the implant gaining adoption in this group and taking some treatment demand from a patient pool ResMed can serve; weak growth would suggest limited expansion of that alternative. This does not describe all CPAP users or, by itself, establish the direction of ResMed’s overall device demand.
